APA (7th ed.) Citation

S, H., N, Y., JY, C., GK, L., BC, A., Y, L., . . . JY, H. (2025). VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. MedComm, 6(9), e70335. https://doi.org/10.1002/mco2.70335

Chicago Style (17th ed.) Citation

S, Hong, et al. "VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer." MedComm 6, no. 9 (2025): e70335. https://doi.org/10.1002/mco2.70335.

MLA (9th ed.) Citation

S, Hong, et al. "VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer." MedComm, vol. 6, no. 9, 2025, p. e70335, https://doi.org/10.1002/mco2.70335.